Monte Rosa's CCNE1 Degrader Shows Promising Tumor Regression in Preclinical Trials
Event summary
- Monte Rosa Therapeutics presented preclinical data at AACR 2026 showing deep tumor regressions in CCNE1-amplified ovarian, breast, and gastric cancer models using MRT-55811.
- MRT-55811 demonstrated superior selectivity and reduced off-target activity compared to CDK2 inhibitors.
- Oral presentation scheduled for April 21, 2026, at 2:30 p.m. PT at AACR Annual Meeting.
- Company anticipates submitting an IND for MRT-55811 later in 2026.
The big picture
Monte Rosa's presentation at AACR 2026 highlights the growing potential of molecular glue degraders in oncology, particularly for targeting previously undruggable oncogenes like CCNE1. The company's ability to demonstrate superior selectivity over existing CDK2 inhibitors positions it favorably in the competitive landscape of targeted cancer therapies. The strategic focus on CCNE1-amplified tumors addresses a significant unmet medical need across multiple cancer types, potentially expanding the addressable market for its pipeline.
What we're watching
- Regulatory Timing
- Whether Monte Rosa can meet its IND submission target for MRT-55811 by the end of 2026.
- Clinical Translation
- How preclinical tumor regression data for MRT-55811 will translate into human clinical trials.
- Competitive Advantage
- The pace at which Monte Rosa can leverage its QuEEN™ discovery engine to maintain a lead in targeting undruggable oncogenes.
Related topics